An experimental vaccine has shown promise in delaying the return of deadly brain tumour and also extending the average survival rate from 15 to 26 months, media reports said.The vaccine, SurVaxM developed by US biotech company MimiVax, targets .
A vaccine to slow the progression of the deadliest form of brain cancer has shown promise in early clinical trials by extending the average survival time from 15 to 26 months.